Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns

Pfizer2,039 enrolled

Overview

EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites). Objectives: * Comparison of antimicrobial susceptibility using disc-diffusion method * Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients

n/a n/a

Study Type

OBSERVATIONAL

Enrollment

2,039

Conditions

Infection

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Isolates (as specified in the observational plan) from hospitalised patients Exclusion Criteria: Isolates obtained from outpatients will not be included for the study. Isolates from repeat cultures performed during in-patient follow-up that were previously recruited into the study will be excluded. Isolates identified as commensals or contaminants will be excluded

Locations (12)

Pfizer Investigational Site

Hyderabad, Andhra Pradesh, India

Pfizer Investigational Site

Bangalore, Karnataka, India

Pfizer Investigational Site

Bangalore, Karnataka, India

Outcomes

Primary Outcomes

Comparison of antimicrobial susceptibility using disc-diffusion method

Time frame: duration of trial

Secondary Outcomes

Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients

Time frame: duration of trial

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.